Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after
allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD is associated …

Given the increasing incidence of chronic graft-versus-host disease (cGVHD) and its rapidly
escalating costs due to many lines of drug treatments, we aimed to perform a meta-analysis …

Acute and chronic graft-vs.-host disease (aGvHD and cGvHD) are major complications after
allogeneic hematopoietic cell transplantation (HCT) leading to substantial morbidity and …

Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell
transplantation is still associated with significant morbidity and mortality. First-line treatment …

Despite advances that have improved survival after allogeneic hematopoietic stem cell
transplantation (HCT), chronic graft-versus-host disease (GVHD) remains a leading cause of …

Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses
one of the most vexing challenges faced by providers who care for patients after allogeneic …

Chronic graft-versus-host disease (GvHD) remains a significant cause of late morbidity and
mortality following allogeneic stem cell transplantation. However, patients with chronic …

Chronic graft-versus-host disease (GVHD) occurs in approximately 60% of patients who
survive for more than 100 days after receiving an allogeneic marrow or peripheral blood …

Chronic graft-versus-host disease (cGVHD) is a complication of hematopoietic cell
transplantation (HCT). Although the clinical outcomes of cGVHD are well documented, few …

Positive results from recent clinical trials have significantly expanded current therapeutic
options for patients with chronic graft-versus-host disease (GVHD). However, new insights …